CDK4 and neoplasm: Treatment with GLR2007 inhibited cell proliferation to an extent equivalent to or greater than CDK4/6 inhibitor abemaciclib in 77 (89.5%) of the 86 mammalian tumor cell lines tested (Supplementary Table 1).